Rocket Pharmaceuticals, Inc. – NASDAQ:RCKT

Rocket Pharmaceuticals stock price today

$2.97
-8.78
-74.72%
Financial Health
0
1
2
3
4
5
6
7
8
9

Rocket Pharmaceuticals stock price monthly change

-47.78%
month

Rocket Pharmaceuticals stock price quarterly change

-47.78%
quarter

Rocket Pharmaceuticals stock price yearly change

-63.21%
year

Rocket Pharmaceuticals key metrics

Market Cap
1.20B
Enterprise value
1.04B
P/E
-5.52
EV/Sales
N/A
EV/EBITDA
-4.87
Price/Sales
N/A
Price/Book
2.36
PEG ratio
0.24
EPS
-2.86
Revenue
N/A
EBITDA
-251.30M
Income
-249.31M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Rocket Pharmaceuticals stock price history

Rocket Pharmaceuticals stock forecast

Rocket Pharmaceuticals financial statements

Average Price Target
Last Year

$40.67

Potential upside: 1269.24%

Based on estimate of 2 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT): Profit margin
Jun 2023 0 -65.70M
Sep 2023 0 -61.89M
Dec 2023 10.31M -59.66M -578.55%
Mar 2024 0 -62.05M
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT): Debt to assets
Jun 2023 461781000 58.81M 12.74%
Sep 2023 598762000 57.67M 9.63%
Dec 2023 566341000 73.76M 13.03%
Mar 2024 499442000 57.94M 11.6%
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT): Cash Flow
Jun 2023 -50.86M 31.20M 182K
Sep 2023 -57.14M 48.25M 189.48M
Dec 2023 -29.33M -140.80M 391K
Mar 2024 -56.88M 35.03M 1.21M

Rocket Pharmaceuticals alternative data

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT): Employee count
Aug 2023 240
Sep 2023 240
Oct 2023 240
Nov 2023 240
Dec 2023 240
Jan 2024 240
Feb 2024 240
Mar 2024 268
Apr 2024 268
May 2024 268
Jun 2024 268
Jul 2024 268

Rocket Pharmaceuticals other data

66.26% -33.74%
of RCKT is owned by hedge funds
45.15M -30.71M
shares is hold by hedge funds

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT): Insider trades (number of shares)
Period Buy Sel
Jan 2024 0 638
Feb 2024 0 48318
Mar 2024 0 276490
Apr 2024 0 93365
May 2024 0 15963
Jul 2024 0 3838
Aug 2024 0 15730
Oct 2024 0 3997
Nov 2024 0 18078
Transaction Date Insider Security Shares Price per share Total value Source
Sale
MILITELLO JOHN officer: See Remarks
Common Stock 1,224 $13.05 $15,978
Sale
PATEL KINNARI officer: See Remarks
Common Stock 4,588 $13.05 $59,892
Sale
SHAH GAURAV director, officer.. Common Stock 11,091 $13.05 $144,782
Sale
WILSON MARTIN officer: General Counsel
Common Stock 1,175 $13.05 $15,338
Sale
WHITE MARK ANDREW officer: See Remarks
Common Stock 3,080 $16.63 $51,205
Sale
MILITELLO JOHN officer: See Remarks
Common Stock 917 $16.63 $15,245
Sale
MILITELLO JOHN officer: See Remarks
Common Stock 1,064 $18.5 $19,688
Sale
PATEL KINNARI officer: See Remarks
Common Stock 3,989 $18.5 $73,812
Sale
SHAH GAURAV director, officer.. Common Stock 9,650 $18.5 $178,564
Sale
WILSON MARTIN officer: General Counsel
Common Stock 1,027 $18.5 $19,004
Insider Compensation
Dr. Gaurav D. Shah (1975) Chief Executive Officer & Director $1,040,000
Ms. Kinnari Patel M.B.A., Pharm.D., PharmD, MBA (1979) Pres, Chief Operating Officer & Head of Devel.
$825,900
Mr. Jonathan Schwartz (1964) Chief Medical Officer & Senior Vice President of Clinical Devel. $619,700
Mr. John C. Militello CPA, CPA (1973) Vice President, Senior Controller & Principal Accounting Officer
$385,780
Wednesday, 18 December 2024
investopedia.com
Tuesday, 10 December 2024
businesswire.com
Wednesday, 27 November 2024
marketbeat.com
Tuesday, 26 November 2024
businesswire.com
Tuesday, 19 November 2024
benzinga.com
Monday, 18 November 2024
businesswire.com
Tuesday, 12 November 2024
businesswire.com
Monday, 11 November 2024
zacks.com
https://thefly.com
Friday, 8 November 2024
businesswire.com
Thursday, 19 September 2024
seekingalpha.com
Wednesday, 18 September 2024
zacks.com
Monday, 9 September 2024
zacks.com
Monday, 29 July 2024
seekingalpha.com
Tuesday, 2 July 2024
zacks.com
Friday, 28 June 2024
investopedia.com
businesswire.com
Wednesday, 5 June 2024
zacks.com
Wednesday, 29 May 2024
businesswire.com
Friday, 10 May 2024
businesswire.com
Tuesday, 7 May 2024
Zacks Investment Research
Tuesday, 30 April 2024
Zacks Investment Research
Friday, 5 April 2024
Seeking Alpha
Wednesday, 3 April 2024
Zacks Investment Research
Tuesday, 2 April 2024
Seeking Alpha
Wednesday, 27 March 2024
Zacks Investment Research
Friday, 1 March 2024
Seeking Alpha
Tuesday, 27 February 2024
Zacks Investment Research
Monday, 22 January 2024
InvestorPlace
Wednesday, 15 November 2023
Zacks Investment Research
  • What's the price of Rocket Pharmaceuticals stock today?

    One share of Rocket Pharmaceuticals stock can currently be purchased for approximately $2.97.

  • When is Rocket Pharmaceuticals's next earnings date?

    Unfortunately, Rocket Pharmaceuticals's (RCKT) next earnings date is currently unknown.

  • Does Rocket Pharmaceuticals pay dividends?

    No, Rocket Pharmaceuticals does not pay dividends.

  • How much money does Rocket Pharmaceuticals make?

    Rocket Pharmaceuticals has a market capitalization of 1.20B.

  • What is Rocket Pharmaceuticals's stock symbol?

    Rocket Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "RCKT".

  • What is Rocket Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Rocket Pharmaceuticals?

    Shares of Rocket Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Rocket Pharmaceuticals's key executives?

    Rocket Pharmaceuticals's management team includes the following people:

    • Dr. Gaurav D. Shah Chief Executive Officer & Director(age: 50, pay: $1,040,000)
    • Ms. Kinnari Patel M.B.A., Pharm.D., PharmD, MBA Pres, Chief Operating Officer & Head of Devel.(age: 46, pay: $825,900)
    • Mr. Jonathan Schwartz Chief Medical Officer & Senior Vice President of Clinical Devel.(age: 61, pay: $619,700)
    • Mr. John C. Militello CPA, CPA Vice President, Senior Controller & Principal Accounting Officer(age: 52, pay: $385,780)
  • How many employees does Rocket Pharmaceuticals have?

    As Jul 2024, Rocket Pharmaceuticals employs 268 workers.

  • When Rocket Pharmaceuticals went public?

    Rocket Pharmaceuticals, Inc. is publicly traded company for more then 10 years since IPO on 18 Feb 2015.

  • What is Rocket Pharmaceuticals's official website?

    The official website for Rocket Pharmaceuticals is rocketpharma.com.

  • Where are Rocket Pharmaceuticals's headquarters?

    Rocket Pharmaceuticals is headquartered at 9 Cedarbrook Drive, Cranbury, NJ.

  • How can i contact Rocket Pharmaceuticals?

    Rocket Pharmaceuticals's mailing address is 9 Cedarbrook Drive, Cranbury, NJ and company can be reached via phone at +60 9 659 8001.

  • What is Rocket Pharmaceuticals stock forecast & price target?

    Based on 2 Wall Street analysts` predicted price targets for Rocket Pharmaceuticals in the last 12 months, the avarage price target is $40.67. The average price target represents a 1269.24% change from the last price of $2.97.

Rocket Pharmaceuticals company profile:

Rocket Pharmaceuticals, Inc.

rocketpharma.com
Exchange:

NASDAQ

Full time employees:

268

Industry:

Biotechnology

Sector:

Healthcare

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.

9 Cedarbrook Drive
Cranbury, NJ 08512

CIK: 0001281895
ISIN: US77313F1066
CUSIP: 77313F106